Share price · TENX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TENX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Aug 2026-89.8%
- 27 Jul 2026+11.4%
Nothing announced by TENX that day or the session before.
- 2 Jul 2026+16.3%
- 1 Jul 2026-8.7%
- 30 Jun 2026+7.8%
- 24 Jun 2026-5.2%
Nothing announced by TENX that day or the session before.
- 23 Jun 2026+11.3%
Nothing announced by TENX that day or the session before.
- 10 Mar 2026+31.7%
- 15 Jan 2026-13.0%
Nothing announced by TENX that day or the session before.
- 14 Jan 2026+21.4%
Nothing announced by TENX that day or the session before.
Share of unusual movement by asset
For each asset, the share of TENX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Levosimendan(Simdax) | Phase 3 | Cardiac troponin C (calcium sensitizer)Small molecule | Heart FailurePulmonary Hypertension due to Left Heart Disease |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $12M | $114M | $17M-$12M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $13M | $118M | $18M-$14M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $12M | $119M | $16M-$9.3M operating cash flow | report ↗ |
| 2025-Q3 | — | $10M | $99M | $16M-$9.2M operating cash flow | report ↗ |
| 2025-Q2 | — | $6.1M | $105M | $11M-$6.3M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $5.7M | $111M | $10M-$7.0M operating cash flow | report ↗ |
| 2024-Q3 | — | $3.1M | $98M | —-$3.1M operating cash flow | report ↗ |
| 2024-Q2 | — | $2.3M | $9.4M | —-$3.0M operating cash flow | report ↗ |
| 2024-Q1 | — | $2.7M | $13M | —-$5.2M operating cash flow | report ↗ |
| 2023-Q3 | — | $1.1M | $11M | —-$2.1M operating cash flow | report ↗ |
| 2023-Q2 | — | $0.2M | $13M | $1.1M-$0.9M operating cash flow | report ↗ |
| 2023-Q1 | — | $0.3M | $14M | —-$1.7M operating cash flow | report ↗ |
| 2022-Q3 | — | $1.5M | $3.8M | —-$3.3M operating cash flow | report ↗ |
| 2022-Q2 | — | $1.5M | $7.2M | —-$3.4M operating cash flow | report ↗ |
| 2022-Q1 | — | $1.2M | $2.9M | $2.7M-$2.9M operating cash flow | report ↗ |
| 2021-Q3 | — | $1.2M | $8.3M+ $0 short-term inv. | —-$3.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $33M | $98M | $13M-$36M operating cash flow | report ↗ |
Tenax Therapeutics reported no revenue for 2025, with R&D expenses of $32.67M, up 157% YoY, and a net loss of $52.6M. Cash and cash equivalents stood at $97.57M as of December 31, 2025.
The company expects its cash to fund operations through 2027. Tenax achieved its randomization target of 230 patients in the Phase 3 LEVEL study, with topline data expected in the third quarter of 2026, and initiated the global Phase 3 LEVEL-2 trial as well as an open-label extension study. In December 2025, a prespecified blinded sample size re-estimation showed the LEVEL study was powered at well over 90% to detect a 25-meter change in six-minute walk distance, and in January 2026 the USPTO issued a Notice of Allowance for subcutaneous levosimendan formulations.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $13M | $95M | $4.4M-$15M operating cash flow | report ↗ |
| 2023-FY | — | $3.2M | $9.8M | —-$5.9M operating cash flow | report ↗ |
| 2022-FY | — | $5.4M | $2.1M | $2.8M-$12M operating cash flow | report ↗ |
| 2021-FY | — | $25M | $5.6M+ $0 short-term inv. | $8.1M-$11M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 19 purchases ($6.5M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-21 | ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% owner | Open-market purchase | 331,979 | $1.66 | $551K | Form 4 |
| 2026-10-20 | ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% owner | Open-market purchase | 254,342 | $1.60 | $406K | Form 4 |
| 2026-10-19 | ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% owner | Open-market purchase | 336,528 | $1.51 | $507K | Form 4 |
| 2026-09-16 | Doogan Declan · director | Open-market purchase | 53,000 | $1.92 | $102K | Form 4 |
| 2026-09-15 | Giordano Christopher Thomas · director, CEO | Open-market purchase | 4,850 | $1.82 | $9K | Form 4 |
| 2026-09-11 | STAAB THOMAS R II · Chief Financial Officer | Open-market purchase | 5,675 | $1.94 | $11K | Form 4 |
| 2026-09-11 | Giordano Christopher Thomas · director, CEO | Open-market purchase | 6,000 | $1.88 | $11K | Form 4 |
| 2026-09-03 | ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% owner | Open-market purchase | 900,000 | $1.78 | $1.6M | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 80 reporting institutions held 21.7M shares ($298.0M, 47.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 1,815,474 | $29.1M |
| 2 | Venrock Adviser, LLC | 1,675,262 | $26.8M |
| 3 | PERCEPTIVE ADVISORS LLC | 1,447,782 | $23.2M |
| 4 | Ikarian Capital, LLC | 1,017,600 | $16.3M |
| 5 | Stonepine Capital Management, LLC | 975,200 | $15.6M |
| 6 | Logos Global Management LP | 625,000 | $10.0M |
| 7 | MORGAN STANLEY | 596,564 | $9.5M |
| 8 | Velan Capital Investment Management LP | 583,333 | $9.3M |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 540,126 | $8.6M |
| 10 | Point72 Asset Management, L.P. | 533,965 | $8.5M |
| 11 | MILLENNIUM MANAGEMENT LLC | 533,889 | $8.5M |
| 12 | ARMISTICE CAPITAL, LLC | 478,827 | $7.7M |
| 13 | Avidity Partners Management LP | 481,868 | $6.9M |
| 14 | Siren, L.L.C. | 427,141 | $6.8M |
| 15 | TD Asset Management Inc | 399,184 | $6.4M |